MIMEDX CCO granted stock options and restricted shares

Rhea-AI Filing Summary

MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported equity awards on March 4, 2026. She was granted 62,068 stock options at an exercise price of $0.00 per share, increasing her directly held options to 137,862 following the grant.

She also received a grant of 74,163 shares of common stock at $0.00 per share, raising her directly held common shares to 314,637. Footnotes state the common stock grant consists of restricted stock that vests fully on the third anniversary of the grant, and that the options vest in 25% increments on each anniversary of the grant date, in both cases conditioned on continued employment.

Insider Trade Summary

Grant/Award: 136,231 shares

Grant/Award 2 txns

Insider Maersk-Moller Kimberly

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	62,068	$0.00	$0.00
Grant/Award	Common Stock	74,163	$0.00	$0.00

Holdings After Transaction: Stock Options — 137,862 contracts (Direct); Common Stock — 314,637 shares (Direct)

Footnotes (3)

1. F1. Represents grant of restricted stock which vests fully on the third anniversary of the grant, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement.
2. F2. Includes 3,492 shares acquired on January 30, 2026 pursuant to the MiMedx Group, Inc. Employee Stock Purchase Plan.
3. F3. The options granted to the reporting person shall vest 25% on each anniversary of the grant date, subject to the reporting person's continued employment as specified in the Nonqualified Stock Option Agreement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MDXG Chief Commercial Officer report on March 4, 2026?

Kimberly Maersk-Moller reported equity awards on March 4, 2026, including 62,068 stock options and 74,163 shares of common stock granted at $0.00 per share, reflecting compensation awards rather than open-market purchases or sales.

How many MIMEDX (MDXG) stock options were granted to the Chief Commercial Officer?

The Chief Commercial Officer received 62,068 stock options as a grant. After this award, her total directly held options rose to 137,862. These options vest 25% on each anniversary of the grant date, subject to her continued employment with the company.

What restricted stock grant did MIMEDX (MDXG) report for its Chief Commercial Officer?

She was granted 74,163 shares of common stock as restricted stock. According to the disclosure, this restricted stock vests fully on the third anniversary of the grant date, provided she remains employed as specified in the Restricted Stock Unit Agreement.

How many MIMEDX (MDXG) common shares does the Chief Commercial Officer own after these grants?

Following the March 4, 2026 awards, she directly holds 314,637 shares of common stock. This figure includes prior holdings and the new restricted stock grant, as well as 3,492 shares previously acquired through the Employee Stock Purchase Plan.

Were the MIMEDX (MDXG) insider transactions open-market buys or compensation awards?

The reported transactions are compensation awards, not open-market activity. Both the 62,068 stock options and 74,163 common shares were granted at $0.00 per share under company equity plans, with vesting tied to continued employment conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 05:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maersk-Moller Kimberly

(Last) (First) (Middle)

1775 WEST OAK COMMONS COURT

(Street)

MARIETTA GA 30062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		74,163(1)	A	$0	314,637(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$5.1	03/04/2026		A		62,068		(3)	03/03/2033	Common Stock	62,068	$0	137,862	D

Explanation of Responses:

1. Represents grant of restricted stock which vests fully on the third anniversary of the grant, subject to the reporting person's continued employment as specified in the Restricted Stock Unit Agreement.

2. Includes 3,492 shares acquired on January 30, 2026 pursuant to the MiMedx Group, Inc. Employee Stock Purchase Plan.

3. The options granted to the reporting person shall vest 25% on each anniversary of the grant date, subject to the reporting person's continued employment as specified in the Nonqualified Stock Option Agreement.

Remarks:

	/s/ William F. Hulse, as attorney-in-fact for Kimberly Maersk-Moller	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.